Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Gene therapy sits at the center of this dementia and brain health question.
Gene therapy for Alzheimer’s disease represents a fundamentally different approach to treatment than medications families may already be familiar with. Rather than targeting the protein plaques and tangles that accumulate in the Alzheimer’s brain, gene therapy aims to prevent neurons from dying in the first place by delivering genetic instructions directly into brain cells. This distinction matters because it opens a new avenue for slowing or stopping cognitive decline at earlier stages of disease—potentially before significant damage occurs. Families should understand that while gene therapy research is still in early stages, recent clinical trial results from 2025 show promise, with a Phase 1 study at UC San Diego demonstrating that the approach is safe in humans and can restore brain activity in treated regions.
The reality is more nuanced than headlines often suggest. Gene therapy is not yet a cure, and it will not become widely available for years. What families need to know is that research is advancing rapidly, multiple drug approaches are being tested simultaneously, and certain families with specific genetic forms of Alzheimer’s may have opportunities to participate in trials that could directly benefit their relatives. Understanding the current state of this research helps families make informed decisions about monitoring, testing, and whether clinical trial participation might be right for them.
Table of Contents
- How Does Gene Therapy Work for Alzheimer’s Disease?
- What Did the 2025 UCSD Gene Therapy Trial Actually Show?
- How Does Gene Therapy Compare to Other Alzheimer’s Treatments?
- What Do Families Need to Know About Research Networks Like DIAN?
- What Are the Important Limitations and Uncertainties Families Should Understand?
- How Do Amyloid-Reducing Drugs Fit Into the Research Picture?
- What Does the Future Hold for Alzheimer’s Research and Families?
- Conclusion
How Does Gene Therapy Work for Alzheimer’s Disease?
gene therapy uses a harmless virus as a delivery vehicle—much like a molecular postal service—to carry genetic instructions directly into brain cells. In the case of Alzheimer’s research, scientists are focusing on delivering instructions for producing more brain-derived neurotrophic factor, or BDNF, a protein that acts as brain fertilizer. BDNF supports neuron survival and function, essentially telling brain cells to stay healthy and maintain their connections. This is a departure from other treatments that try to clean up the protein mess that has already accumulated; instead, gene therapy attempts to strengthen the brain’s natural defenses before or during early decline. The UC San Diego trial demonstrates how this works in practice. Researchers surgically injected the gene therapy directly into the entorhinal cortex, a brain region critical for memory formation that deteriorates in Alzheimer’s disease.
The therapy worked by having the brain cells themselves manufacture BDNF locally, rather than relying on a drug to circulate throughout the body and cross the blood-brain barrier—a notoriously difficult task. This local approach is more efficient and allows higher concentrations of the protective protein exactly where it’s needed. The key limitation families should understand is that gene therapy, at least in current trials, requires brain surgery. A neurosurgeon must precisely inject the viral vector into specific regions of the brain. This carries inherent surgical risks and makes the approach feasible only for carefully selected patients in controlled research settings. It is not a simple pill or infusion like some other Alzheimer’s treatments. For many families, this reality means gene therapy may remain a specialized option rather than a mainstream treatment for years to come.
What Did the 2025 UCSD Gene Therapy Trial Actually Show?
In July 2025, researchers presented data from the ongoing Phase 1 trial at the Alzheimer’s Association International Conference in Toronto. Six patients with mild Alzheimer’s disease had received the AAV2-BDNF gene therapy, and the results showed something remarkable: the treatment was safe, with no serious adverse events reported in the treated patients. More importantly, brain imaging using FDG-PET scans—which measure how much glucose (energy) brain cells are using as a marker of activity—showed that the treated entorhinal cortex region maintained or improved its activity levels. This contrasts sharply with what normally happens in Alzheimer’s disease, where these same brain regions show progressive decline in activity over time. To put this in perspective, the trial included only 12 participants total, with 6 receiving treatment in the mild Alzheimer’s disease cohort and treatment of a mild cognitive impairment cohort beginning.
These numbers are small, which is typical for Phase 1 trials designed primarily to test safety rather than effectiveness. The fact that the brain activity actually improved rather than declining—even in a small group—suggests the therapy is doing something meaningful at the cellular level. However, families must understand that improved brain activity on imaging does not automatically translate to improved memory or thinking in daily life; longer-term follow-up and larger trials are needed to determine whether patients notice cognitive benefits. The trial also enrolled a cohort of patients with mild cognitive impairment, who were just beginning to receive treatment at the time the 2025 data were presented. This group represents the earlier stages of cognitive decline, suggesting researchers are testing whether treating earlier might yield better results. However, full results from this cohort were not yet available, so families hoping for evidence that treating earlier prevents progression will need to wait for additional data.
How Does Gene Therapy Compare to Other Alzheimer’s Treatments?
The Alzheimer’s treatment landscape now includes several different approaches, and families often ask how they relate. Lecanemab (Leqembi) and donanemab (Kisunla) are FDA-approved drugs that target beta-amyloid, one of the protein plaques that accumulates in Alzheimer’s brains. These drugs work by removing amyloid, essentially trying to clean up the mess. In clinical trials, most people treated with these amyloid-targeting drugs transitioned from amyloid-positive (having brain amyloid on scans) to amyloid-negative after 18 months of treatment. However, removing amyloid alone does not stop all cognitive decline—it slows it, which is an important but modest benefit. Gene therapy takes a different approach entirely. Rather than removing accumulated proteins, it attempts to strengthen the brain’s inherent survival mechanisms, helping neurons resist dying even in the face of amyloid and tau tangles.
Think of it as the difference between cleaning a house that’s falling apart versus reinforcing its foundation. Some researchers believe that combining both approaches—using amyloid-reducing drugs while also supporting neuron survival through gene therapy—might ultimately prove most effective. This combination strategy is not yet being tested, but it represents a logical next step once gene therapy moves beyond Phase 1 trials. The major difference families should recognize is in timing and stage of disease. Amyloid-targeting drugs like lecanemab are approved for mild cognitive impairment or mild dementia with confirmed amyloid; they require brain imaging to confirm amyloid burden before starting. Gene therapy in current trials is also being tested in mild stages, but the surgical nature of delivery limits who can access it. Meanwhile, early prevention trials with amyloid-reducing drugs in asymptomatic people with brain amyloid suggest that very early treatment—even before symptoms appear—may delay disease onset. This suggests a potential future where different treatments target different stages: early prevention, symptomatic slowing, and supportive therapy.
What Do Families Need to Know About Research Networks Like DIAN?
The Dominantly Inherited Alzheimer Network (DIAN) includes more than 200 families worldwide who carry rare gene mutations that cause Alzheimer’s disease with early onset, typically in the early 40s to mid-50s. These families represent approximately 1% or less of all Alzheimer’s cases, but they are extraordinarily valuable to research because their disease is predictable—each child of an affected parent has a 50-50 chance of inheriting the mutation. DIAN operates across more than 40 sites in 18 countries, creating a global research partnership that allows scientists to enroll participants, track them over time, and test interventions in this well-characterized population. For families in DIAN and similar networks, being part of research offers both advantages and responsibilities. These families often have opportunities to access cutting-edge trials, including gene therapy and other experimental treatments, years before they might become available to the general Alzheimer’s population.
They receive extensive monitoring and support from research teams. However, participation also means traveling for appointments, undergoing brain imaging and cerebrospinal fluid testing, and living with the knowledge that one carries a disease-causing mutation—knowledge that can affect family planning, career decisions, and psychological well-being. Many families in these networks have made remarkable contributions to science, essentially volunteering their families’ health history to accelerate progress for everyone. For families outside these rare-mutation networks—the vast majority—Alzheimer’s disease still has genetic components, but inheritance is more complex and less predictable. These families cannot access DIAN trials, but they may be eligible for other research studies testing gene therapy, amyloid-targeting drugs, or other approaches. The key is knowing that research networks exist, understanding what participation entails, and making informed decisions about whether involvement aligns with individual family circumstances and values.
What Are the Important Limitations and Uncertainties Families Should Understand?
Gene therapy research for Alzheimer’s, despite promising early results, carries significant uncertainties that families must weigh carefully. First, the UCSD trial is Phase 1, meaning it primarily tests safety rather than efficacy. The six patients treated represent an extremely small sample, and while improved brain activity on imaging is encouraging, it does not prove that patients experience real-world improvements in memory, daily functioning, or quality of life. Phase 2 and Phase 3 trials—which test whether the treatment actually produces meaningful cognitive benefits—will take years to complete. Families should not interpret early promise as a guarantee of future effectiveness. Second, the surgical delivery method presents a practical barrier and carries inherent risks. Any brain surgery carries risks of infection, bleeding, stroke, and other complications.
For gene therapy to become a practical treatment option for large populations, researchers would need to develop less invasive delivery methods, such as injections into the spinal fluid or intravenous infusions that could cross the blood-brain barrier. These innovations may eventually occur, but they are not yet reality. Currently, access to gene therapy remains limited to carefully selected research participants in controlled settings. Third, there is the matter of timing and progression. Gene therapy appears to work best in early stages of cognitive decline—mild cognitive impairment or mild dementia. This raises a critical question for families: How will people know early enough to benefit? Most people don’t have their first cognitive complaint investigated immediately, and many don’t seek diagnosis until symptoms are more obvious. For gene therapy to make a real difference in Alzheimer’s care, families and healthcare systems will need to recognize early changes in memory and thinking, pursue diagnostic evaluation promptly, and then have brain imaging to assess amyloid burden—all before significant neurodegeneration occurs. This requires a shift in how Alzheimer’s is detected and addressed, which has not yet happened in routine clinical practice.
How Do Amyloid-Reducing Drugs Fit Into the Research Picture?
Lecanemab and donanemab represent the first disease-modifying drugs approved for Alzheimer’s disease that actually slow cognitive decline in symptomatic patients. In clinical trials with mild cognitive impairment or mild dementia patients, these drugs reduced cognitive decline by approximately 25-35% over 18 months—modest but meaningful when considering that untreated Alzheimer’s progresses relentlessly. Beyond the symptomatic population, research is expanding into prevention: a 2025 study showed that anti-amyloid drugs given many years before symptoms appear, in people with genetic mutations or biomarker evidence of early brain changes, can delay the onset of Alzheimer’s dementia. Eight Phase 3 trials are completing in 2026, including the TRAILBLAZER-ALZ 3 trial testing donanemab in asymptomatic individuals who show brain amyloid on imaging but have no cognitive symptoms yet. These prevention trials represent a major shift in Alzheimer’s research strategy—treating people who feel completely normal because biomarkers indicate brain changes.
For families, this approach means that genetic testing and biomarker screening are becoming increasingly important. If a family member carries a disease-causing mutation or shows amyloid on brain imaging before symptoms appear, they may soon have the option to start preventive treatment, potentially delaying symptom onset for years. The relationship between amyloid-reducing drugs and gene therapy remains to be determined. Currently, they are being developed as separate treatment paths. But the logical next step, which researchers are likely to pursue once gene therapy moves beyond Phase 1, would be combination therapy: using amyloid-reducing drugs to address the protein pathology while using gene therapy to strengthen neuron survival. This multimodal approach could potentially be more effective than either treatment alone.
What Does the Future Hold for Alzheimer’s Research and Families?
The trajectory of Alzheimer’s research over the next 5-10 years will be shaped by both scientific advances and funding realities. On the positive side, multiple approaches are being pursued simultaneously—gene therapy, amyloid-reducing drugs, tau-targeting therapies, and others—increasing the likelihood that effective treatments will eventually emerge. The fact that Phase 1 gene therapy showed safety and biological activity is genuinely encouraging. As trials progress and more data accumulate, researchers will better understand which patients benefit most, what the real-world impact on cognition and daily function is, and whether combination approaches offer additional benefit.
However, families should be aware that research networks like DIAN face uncertainty. As of May 2026, the DIAN network is grappling with cuts in federal funding, which threatens the infrastructure that has made large-scale genetic Alzheimer’s research possible. If funding challenges are not resolved, the pace of progress could slow. This situation underscores a broader reality: cutting-edge research depends on sustained investment, and that investment is not always guaranteed. Families hoping to participate in research, or hoping for rapid progress toward treatments, should advocate for continued public funding of Alzheimer’s research while also staying informed about private funding sources and clinical trial opportunities.
Conclusion
Families should understand that gene therapy for Alzheimer’s represents a genuine scientific advance, with early-stage evidence that it is safe and biologically active in the human brain. The UCSD Phase 1 trial data from 2025 shows that the approach can be delivered safely and can restore brain activity in treated regions, contrasting with the expected decline in Alzheimer’s disease. However, this is still early-stage research, and years of additional testing are needed to determine whether gene therapy produces real cognitive benefits, who benefits most, and how it compares to or complements other emerging treatments like amyloid-reducing drugs.
For most families affected by Alzheimer’s disease, gene therapy remains a future possibility rather than a current option. The immediate focus should be on recognizing early cognitive changes, pursuing timely diagnosis, and discussing with healthcare providers whether existing treatments like lecanemab are appropriate. For families with genetic forms of Alzheimer’s or those interested in research participation, clinical trials represent a way to potentially access cutting-edge treatments while contributing to progress. Staying informed about research developments, understanding the difference between early promising results and proven effectiveness, and maintaining realistic expectations will help families navigate the landscape of emerging Alzheimer’s treatments as they continue to evolve.
You Might Also Like
- Can Gene Therapy Change the Course of Alzheimer’s?
- What Experimental Gene Therapy Could Mean for Brain Disease
- How Gene Therapy May Target Brain Damage Differently
For more, see NIH MedlinePlus — cognitive testing.
